Industries > Pharma > Global Treatment for Neglected Tropical Disease Market 2019-2029

Global Treatment for Neglected Tropical Disease Market 2019-2029

Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease

PAGES: 157
PRODUCT CODE: PHA0396

Clear
WOOCS 2.2.1
SKU: PHA0240 Categories: , , Tag:

The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere.

The 157-page report provides clear detailed insight into the Global Treatment for Neglected Tropical Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Treatment for Neglected Tropical Disease market forecasts from 2019-2029

Global Treatment for Neglected Tropical Disease Market 2017-2027

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by disease type:
– Malaria treatments
– Dengue treatments
– Leishmaniasis
– Schistosomiasis
– Lymphatic Filariasis
– Chagas Disease
– Others

For each disease type, the report provides a SWOT analysis, a list of selected drugs and revenue forecasts from 2019-2029 of the leading drugs.

• This report provides revenue forecast for these leading drugs:
– Coartem (Novartis)
– Clindamycin (Pfizer)
– Dengvaxia (Sanofi)
– AmBisome (Gilead Sciences)
– Impavido (Knight Therapeutics)
– ALBENZA (Amedra Pharmaceuticals LLC)

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by regional and national market:
– North America: US and Canada
– Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
– Asia-Pacific: Japan, China, India, Rest of Asia
– Latin America: Brazil, Mexico, Rest of Latin America
– Middle East & Africa: Saudi Arabia, South of Africa, Rest of Middle East & Africa

Each regional market is further broken down by disease type.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the neglected tropical disease market:
– Pfizer, Inc.
– Bayer
– GlaxoSmithKline plc
– Merck & Co., Inc.
– Novartis International AG
– Takeda Pharmaceutical Company Ltd
– Sanofi S.A.
– Eisai Co., Ltd

Buy our report today Global Treatment for Neglected Tropical Disease Market 2019-2029: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category